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 ABSTRACT 
Small molecules functioning as negative regulators of MDM2 have been considered as 
promising anti-cancer agents. A series of novel anthraquinone (AQ) analogues upregulate p53, a 
well-known tumor suppressor, by inactivating its antagonist protein MDM2. The novel AQ 
compounds synthesized through the modifications on the rhein scaffold were reported to have 
successfully arrested tumor growth. To have a better understanding of their underlying 
metabolism in vivo, pharmacokinetic (PK) studies were performed for the AQ compounds. A 
selective, accurate and reproducible assay methodology for PK study was set up for each AQ 
compound. The stabilities of AQ compounds were then evaluated in terms of different 
pharmacokinetic properties. All AQ compounds were found unstable in plasma or eliminated 
from the systemic circulation in mice rapidly possibly due to their chemical instability or rapid 
hepatic metabolism. The correlation between in-vitro stability and in-vivo metabolism can give a 
predictable guide for future PK studies. 
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CHAPTER 1 INTRODUCTION 
p53 has been intensively studied because of its indisputable role as an important tumor 
suppressor, which can arrest cell cycle of aberrant cells. p53 can also promotes cell apoptosis, 
and the major tumor-apoptotic function of p53 involves perturbating mitochondrial membranes 
and releasing apoptogenic factors [4] in response to stress stimuli, such as DNA damage, 
hypoxia and erosion of telomere [5]. The released apoptogenic factors subsequently trigger cell 
death by activating caspase pathway [6]. p53 encodes pro-apoptotic proteins BAX, PUMA and 
NOXA, which consequently regulates the permeability of mitochondrial membrane, and thus 
causes cell apoptosis through the mitochondrial pathway mentioned above [4]. Abnormalities of 
p53 have been found in over 50% of human tumors [1,2], and an increased tendency of 
malignant transformation has been reported closely relevant to p53 loss or mutation [3]. 
Therefore, stabilization or re-activation of wild-type p53 (wt-p53) has been considered as a 
promising anti-cancer therapeutic strategy [7]. Oncoprotein murine double minute-2 (MDM2) 
encoded by murine double minute-2 gene is a negative regulator of p53 [8,9]. A variety of 
human cancers, including breast cancer [10,11], glioblastoma multiforme [12] and leukemia [13], 
have been recorded to have high levels of MDM2. MDM2 overexpression is resulted from 
MDM2 gene amplification or increased translation [17], which strongly suppresses wt-p53 
almost exclusively [14]. MDM2 directly binds to the N-terminal of p53. Upon the interaction 
with MDM2, p53 loses its capability of binding with its target DNA as a transcriptional factor. 
On the other hand, E3 ligase of MDM2 degrades p53 by ubiquitination in a proteasome-
dependent manner. Through these two downregulatory mechanisms, MDM2 successfully stifles 
wt-p53 [9,15,16].  
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A homology of MDM2 called MDMX (MDM4 in mice) has the similar structure of 
MDM2 [18] which can bind to p53 with high affinity [19]. MDMX is unable to degrade p53, but 
it functions as a guard for MDM2 and prevents MDM2 from inactivation [20]. Many attempts 
have been programmed to liberate p53 from binding with MDM2 by different approaches, giving 
rise to the activation of p53 apoptosis pathway [21-23]. These approaches include blocking the 
expression of MDM2 [24], deactivating of MDM2 E3 ligase for anti-ubiquitination [25] and 
interfering the interaction between MDM2 and p53 [26,27]. Accordingly, many small-molecule 
compounds have been designed to target the E3 ligase of MDM2 [28]. Although some of those 
compounds, such as HLI98, were observed to induce apoptosis by activating p53 pathway in 
p53-dependent way, the low potency and selectively hinders their further application.  
An increasing number of studies have been focused on the invention of small molecules 
which can block MDM2-p53 interaction [29,30]. Nutlins were the first generation of MDM2 
inhibitors identified from cis-imidazoline compounds [31]. They specifically disrupt MDM2-p53 
binding in multiple cell lines, leading to proliferation arrest in cancer cells through stabilization 
of p53 and activation of p53 related pathway. Especially, nutlin-3a has shown a high potency in 
inhibiting wt-p53 cancer cells and high efficacy of arresting tumor-growth in human cancer 
xenograft model [32]. A class of benzodiazepine analogues were found to hamper MDM2-p53 
interaction with IC50s in the range of 0.5 – 2 μM in vitro [33]. These benzodiazepines are able to 
selectively inhibit proliferation cancer cell with functional wt-p53. However, the low potency 
makes them difficult to be further developed as anti-tumor drug [34,35]. RITA, means 
reactivation of p53 and inducing cancer cell apoptosis, is one of another small molecules 
interfering with MDM2-p53 interaction. RITA exerts its anti-cancer activity by binding to p53 
instead of MDM2 likely dependent on wt-p53 [36]. A series of spiro-oxindo analogues have also 
been found can function as blocker of MDM2-p53 interaction but have no significant activity on 
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cancer cells with mutant p53 [37]. These studies indicate the status of p53 matters to antagonists 
of MDM2 for therapeutic targeting, and in most of the cases, wt-p53 is a prerequisite. 
Anthraquinones (AQ) compounds have been proposed to have cytotoxicity due to the 
non-covalent binding to DNA structures likely by intercalation [40,41]. Several highly potent 
anticancer drugs contain anthraquinone scaffold have been developed in clinical application, 
such as doxorubicin and mitoxantrone [38]. However, many of these drugs have severe toxicity 
to normal tissues [39]. Rhein as a natural product also possesses an anthraquinone scaffold and 
exerts low-to-moderate anticancer activity [42-45]. Although human body tolerates rhein [46], 
the low cytotoxicity (IC50: 12-200 μΜ) limits the development of rhein as an anticancer drug 
[42-45], it was found well-tolerated by human body. Therefore, the chemists have made some 
attempts to synthesis the anthraquinone compounds through the modification on rhein scaffold. 
Those novel compounds, which are called AQ compounds, possessing anti-cancer active 
anthraquinone scaffold, are supposed to have high cytotoxicity to tumor cells but low 
cytotoxicity to normal cells. Moreover, the synthesis routes of AQ compounds are more 
simplified and economically-friendly comparing to that of other compounds bearing 
anthraquinone ring such as doxorubicin [47].  
 An AQ analogue termed as AQ-101 were selected as one of the most highly potent AQ 
compound against the proliferation of acute lymphoblastic leukemia cells. Like many of other 
MDM2-p53 inhibitor, AQ-101 downregulates MDM2 by promoting the degradation of MDM2 
protein in a proteasome-dependent way. AQ-101 disturbs the interaction between MDM2 and 
MDMX, which makes MDM2 more susceptible to self-mediated degradation. Moreover, AQ-
101 has minimal cytotoxicity to normal cells, which grants it as a safe and well-tolerated anti-
cancer drug for human [13]. 
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 AQ compounds studied in this thesis are newly synthesized through further modifications 
of AQ-101. These AQ compounds are expected to have the similar or better anti-cancer activity 
as AQ-101 while still being safe to normal tissues. For any promising novel compounds, an 
understanding of their pharmacokinetics is important for clarifying their underlying mechanisms 
in vivo and supporting the prediction of their efficacies. Since adequate analytical methods are 
crucial for performing PK studies, the detection and quantification methods with high sensitivity 
and reproducibility have been developed for each individual AQ compound using high 
performance liquid chromatography (HPLC). However, for compounds tended to degrade in 
aqueous environment or in body fluid, the studies for their in-vitro stabilities were necessary, and 
which may also help to give explanations for the PK properties of the compounds.
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CHAPTER 2 METHODS 
2.1.  Materials and Reagents 
AQ-284, AQ-290, AQ-312 and AQ-313 were synthesized and purified by Dr. Binghe 
Wang’s lab (Department of Chemistry, Georgia State University, Atlanta, GA). α-
Naphthoflavone (α-NF) was purchased from Acros (NJ). HPLC-grade methanol and acetonitrile 
as well as GC-grade dimethyl sulfoxide (DMSO) were from Fisher Scientific (Hampton, NH). 
HPLC-grade triethylamine (TEA) was from EMD Millipore (Sigma-Aldrich, MO). Ultra-pure 
water was prepared by Millipore Direct-Q 3 UV water purification system (MilliporeSigma, 
MA). Sodium phosphate monobasic monohydrate (Fisher Bioreagents, NJ) and sodium 
phosphate dibasic anhydrous (Fisher Scientific, NJ) were used for preparation of sodium 
phosphate buffer.  
2.2.  Apparatus 
Waters HPLC system: Waters 2695 separation module, Waters 996 photodiode array 
detector, Empower computer system (Waters, Milford, MA) and Phenomenex (Torrance, CA) 
Kinetex XB-C18 column (5 μM, 250×4.6 mm); 
Agilent HPLC system: Agilent 1260 Infinity II Quaternary separation module, 1260 
Infinity II DAD HS detector, OpeLab computer system (Agilent, Santa Clara, CA) and 
InfinityLab Poroshell 120 EC-C18 column (2.7 μM, 3.0 × 150 mm). 
 
 
6 
2.3. HPLC Analytical Conditions 
2.3.1. HPLC methodology under Waters HPLC system 
For AQ-284 and AQ-290, a gradient mobile phase consisting of methanol (solvent A) and 
sodium phosphate buffer (10 mM, pH 6.8, 10 mM of TEA) (solvent B) was used for a gradient 
elution. The flow rate was 1 mL/min with a column temperature of 40 ℃. The gradient elution 
for AQ-284 is illustrated as following: 0 – 12 min, 48% A; 12.01 – 25 min, 68 – 80% A; 25.01 – 
28 min, 48% A. The gradient elution for AQ-290 has shown as following: 0 – 7 min 65% A; 7.01 
– 13 min, 75% A; 13.01 – 16 min, 65% A. The AQ-284 was eluted at 13 min with a detection 
wavelength of 258 nm followed by the α-NF was eluted at 23 min with a detection wavelength of 
280 nm. The AQ-290 was eluted at 8 min with a detection wavelength of 226 nm followed by α-
NF eluted at 13.5 min.  
2.3.2. HPLC methodology under Agilent system 
For AQ-312 and AQ-313, a gradient mobile phase consisting of methanol (solvent A) and 
sodium phosphate buffer (10 mM, pH 6.8) (solvent B) was used for a gradient elution. The flow 
rate was 0.4 mL/min with a column temperature of 35 ℃. The gradient elution for AQ-312 has 
illustrated as following: 0 – 7 min, 52% A; 7.01 – 16.00 min, 75% A; 16.01 – 19 min, 52% A. 
The gradient elution for AQ-313 has illustrated as following: 0 – 5 min, 50% A; 5.01 – 15 min, 
75% A; 15.01 – 18 min, 50% A. The retention time of AQ-312 was 7 min with a detection 
wavelength of 258 nm followed by the α-NF eluted at 15.8 min with a detection wavelength of 
280 nm. The AQ-313 was eluted at 5 min with a detection wavelength of 282 nm followed by 
the α-NF eluted at 15.4 min. 
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2.4.  Preparation of Standard Samples 
The stock solutions for all AQ compounds were prepared in DMSO at concentration of 
10 mM. A series of working stocks was prepared by diluting the 10 mM stock to concentrations 
of 2 mM, 1 mM, 500 μM, 200 μM and 100 μM. The stock for α-NF was prepared in DMSO at 
concentration of 200 μM. All stocks were stored at -20 ℃ and taken to room temperature (25 ℃) 
before use.  
Standard samples with three different concentrations used for plotting calibration curves 
were prepared by spiking the working stock in mobile phase or in plasma collected from black 
mice.  The concentrations of AQ compounds for calibration was chosen as 1 – 20 μM, and that 
of α-NF was 2 μM. The calibration curves established in plasma were used for calculating drug 
concentration in vivo following PK study. 
2.5.  Plasma Extraction 
The plasma samples containing the AQ compounds were extracted by organic solvents at 
10 times the volume of plasma by vortex-mixing. AQ-313 was extracted using acetonitrile after 
5-min vortex-mixing at room temperature. Extraction for AQ-284 and AQ-290 was performed 
by adding ice-cold ethyl and vortex-mixing for 25 min at 4 ℃; For AQ-312, an iced-cold 
mixture of ethyl acetate and acetonitrile (1:1 = v/v) (5 times the volume of ethyl acetate followed 
by 5 the times volume of acetonitrile) was applied as solvent for extraction, and optimal vortex-
mixing time was determined as 15 min at room temperature. The upper organic layer following 
centrifugation (15,000 rpm, 5 min) was transferred and evaporated to dryness at 35 ℃. The dried 
residue was reconstituted in 100 μL of mobile phase (methanol and phosphate buffer) and 
subjected to HPLC analysis. 
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2.6.  HPLC Methodology Validation 
2.6.1. Selectivity and specificity 
Chromatograms of blank plasma, plasma spiked with AQ compounds and mobile phase 
spiked with AQ compounds were compared to determine the selectivity of HPLC methodology. 
This assay is aimed for checking the possible endogenous interference. 
2.6.2. Linearity assessment and Lower Limit of Quantification (LLoQ) 
Standard samples for plotting calibration curves were prepared following the instruction 
in Section 2.4. Calibration curves were established by plotting the ratios of the peak areas of AQ 
compounds to the peak areas of α-NF versus concentration of AQ compounds. The linear 
relationship of the HPLC methodology was evaluated by assessing the linearity of calibration 
curves. For AQ-284 and AQ-290, the calibrate concentrations were 2 μM, 10 μM and 20 μM; for 
AQ-312 and AQ-313, the calibrate concentrations were 1 μM, 10 μM and 20 μM. The LLoQ was 
defined as the lowest analytical concentration of standard, which gives a signal-to-noise ratio 
higher than 10.  
2.6.3. Accuracy and precision 
The intra- and inter- day accuracy and precision of the assay for each compound were 
performed by analyzing three replicates for the standard samples of AQ compounds at three 
different concentration levels (1 μM, 10 μM, 20 μM) over three different days. The 
concentrations were calculated by calibration curve established every day. Accuracy was 
demonstrated as relative error (RE), and RE = (measured concentration – nominal value of 
concentration) / (nominal value of concentration) × 100%. Precision was determined as relative 
standard deviation (RSD). The RSD should be less than 15% and RE should be less than ± 15%.  
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2.6.4. Recovery from plasma extraction 
The recoveries of AQ compounds or α-NF in plasma samples were calculated by 
comparing the peak areas of extracted AQ compounds or α-NF with the peak areas of the 
compounds derived from samples spiked in mobile phase. Three different concentration levels of 
AQ compounds (1 μM or 2 μM, 10 μM, 20 μM) as well as α-NF at 2 μM were determined. Each 
concentration level subjected to triplicate verification by HPLC. 
2.7.  Pharmacokinetic Study 
Pharmacokinetic study for AQ compounds were evaluated in mice following intravenous 
(IV) injection. The vehicle used for IV administration was DMSO. AQ-284 and AQ-313 were 
dosed at 10 mg/kg, AQ-290 was dosed at 15 mg/kg, and AQ-312 was dose at 6.8 mg/kg. Blood 
was collected by retro-orbital withdrawal following IV injection in mice. Plasma was obtained 
by centrifugation (15,000 rpm, 4 ℃) of whole blood for 5 min, extracted by methods in Section 
2.5 and analyzed by HPLC. 
2.8.  Stability Studies  
The stability studies of AQ compounds were performed by incubating the compound in 
plasma or in sodium phosphate buffer (pH 7.4). The AQ compounds were spiked into pre-heated 
blank plasma at concentrations of 20 μΜ with 2 μΜ of α-NF. After incubation at 37 ℃ for 2 – 
30 min, the plasma samples were processed by methods in Section 2.5 and analyzed by HPLC.  
The stability of AQ compounds in aqueous solution was tested by spiking and incubating 
the compound in sodium phosphate buffer (pH 7.4). The concentration for each AQ compound 
was 20 μM, and 2 μM of α-NF was added as the internal standard. After incubation at 37 ℃ for 
10 min – 24 h, each sample was analyzed by HPLC. Drug concentrations of the incubated 
samples were calculated by calibration curves and compared with freshly prepared samples at the 
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same concentrations spiked in plasma or in sodium phosphate buffer. The stabilities of AQ 
compounds were indicated as half-life (t1/2), which is the time for drug fall to half of its original 
concentration. 
2.9.  Influence of Hemolysis 
Studies were performed to test whether hemolysis caused by DMSO in vivo will impair 
the integrity of AQ compounds. The DMSO stocks of AQ-284 and AQ-312 were added into 
fresh whole blood collected from mice. After vortex-mixing for 3 min, the whole blood was 
centrifuged (15, 000 rpm, 5 min) at 4 ℃. The upper plasma layer following centrifugation 
looked reddish indicating the occurrence of hemolysis. The plasma layer was transferred into a 
clean tube, and then the α-NF was added into plasma at concentration of 2 μM. The plasma 
samples were processed using the extraction method in Section 2.5 and analyzed by HPLC. 
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CHAPTER 3 RESULTS 
3.1. Plasma Extraction Optimization 
Acetonitrile precipitates proteins in plasma and minimizes the influence of endogenous 
noise in the final samples. All AQ compounds were initially tried extracting by acetonitrile, but 
only the extraction for AQ-313 had a high recovery. The amount of acetonitrile for AQ-313 
extraction was optimized as 10 times volume of plasma, and the 5-min vortex-mixing was 
enough for a thorough extraction. The extraction of AQ-284 and AQ-290 using ice-cold ethyl 
acetate (10 times the volume of plasma) at a cold condition (4 ℃) rendered high recoveries of 
the compounds. Since a complete liquid-liquid extraction needs prolonged time, different 
extraction time ranged from 5 min to 40 min were tried, and the optimal was decided as 25 min. 
For AQ-312, the extraction by ethyl acetate had a high recovery, however, a peak of endogenous 
constituent interfered with the AQ-312 peak and was unable to be separated by gradient elution 
under Agilent HPLC analyzing system. Acetonitrile (5-times the volume of plasma) was added 
into ethyl acetate (5 times the volume of plasma) for the elimination of endogenous interference 
by precipitating proteins while did not compromise the recovery. 
3.2.  HPLC Methodology Validation 
3.2.1. Selectivity and specificity 
The chromatograms of AQ compounds in mobile phase have been shown in Figure 3-1(a) 
(AQ-284), and Figure 3-2(a) (AQ-290), Figure 3-3(a) (AQ-312) and Figure 3-4(a) (AQ-313). In 
comparison, the chromatograms of plasma samples spiked with AQ compounds have been
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shown in (c) of Figure 3-1 to Figure 3-4. As references, the chromatograms of blank plasma 
under optimal elution gradients for all AQ compounds are shown in (b) of Figure 3-1 to Figure 
3-4. 
 
(a)  
(b)  
 
(c)  
 
 
Figure 3-1 HPLC chromatograms of AQ-284: (a) mobile phase spiked with 20 μΜ; (b) blank 
plasma; (c) plasma spiked with 20 μΜ.  
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(a)  
(b) 
(c)  
 
Figure 3-2 HPLC chromatograms of AQ-290: (a) mobile phase spiked with 20 μΜ; (b) blank 
plasma; (c) plasma spiked with 20 μΜ.  
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(a)   
(b)  
(c)   
 
Figure 3-3 HPLC chromatograms of AQ-312: (a) mobile phase spiked with 20 μΜ; (b) blank 
plasma; (c) plasma spiked with 20 μΜ. 
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(a)  
(b) 
(c)  
 
Figure 3-4 HPLC chromatograms of AQ-313: (a) mobile phase spiked with 20 μΜ; (b) blank 
plasma; (c) plasma spiked with 20 μΜ.  
 
No endogenous peak was observed at the retention time of AQ compounds (AQ-284: 13 
min, AQ-290: 8 min, AQ-312: 7 min, AQ-313: 5 min) or α-NF (retention times were different 
depending on variable HPLC methodology), which indicates a complete resolution without 
interferences. 
3.2.2. Linearity and LLoQ 
Calibration curves for AQ compounds established in plasma in vitro were linear. The 
equations for the calibration curves of AQ compounds were: y = 0.2101x – 0.0977 (AQ-284, r = 
0.9982), y = 0.085x – 0.0188 (AQ-290, r = 0.9931), y = 0.1668x + 0.02 (AQ-312, r = 0.9998) 
280 nm 282 nm 
α-NF 
280 nm 282 nm 
AQ-313 
α-NF 
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and y = 0.2744x – 0.0145 (AQ-313, r = 0.9996). The correlation coefficient (r) for each curve 
was higher than 0.99, indicating a good linearity. The values of LLoQ for AQ-284 and AQ-290 
were determined as 2 μΜ, and the values of LLoQ for AQ-312 and AQ-313 was determined as 1 
μΜ. 
3.2.3. Accuracy and precision 
The intra- and inter-day accuracy was performed for AQ compounds, which were 
summarized in Table 3-1 and Table 3-2. All values of RSD and RE were less than 15%. The 
results have indicated the HPLC methodology for quantification of each AQ compound was 
accurate, precise and reproducible during daily laboratory operation. 
Table 3-1 Intra-day assay accuracy and precision (n = 3) 
Intra-day accuracy and precision 
Added 
(μM) 
Measured (μM) RSD (%) RE (%) 
AQ-284 AQ-290 AQ-284 AQ-290 AQ-284 AQ-290 
2 2.2 2.2 3.3 2.8 10.0 10.0 
10 11.1 10.1 2.5 1.3 11.0 1.0 
20 21.7 19.9 3.4 2.9 8.5 -0.5 
 AQ-313 AQ-312* AQ-313 AQ-312* AQ-313 AQ-312* 
1 1.0 1.1 1.1 1.1 0 10 
10 9.7 N/A 1.1 N/A -3.0 N/A 
20 21.0 N/A 1.2 N/A 5.0 N/A 
*AQ-312 was only tested at concentration of 1 μM due to the insufficient amount. 
Table 3-2 Inter-day accuracy and precision (n = 3, 3 days) 
Inter-day accuracy and precision 
Added 
(μM) 
Measured (μM) RSD (%) RE (%) 
AQ-284 AQ-290 AQ-284 AQ-290 AQ-284 AQ-290 
2 2.1 2.1 2.7 3.7 5.0 5.0 
10 10.8 10.2 7.0 4.7 8 2.0 
20 21.1 20.7 5.4 3.1 5.5 3.5 
 AQ-313 AQ-312* AQ-313 AQ-312* AQ-313 AQ-312* 
1 1.0 1.1 1.4 1.6 0 10.0 
10 10.2 N/A 1.3 N/A 2.0 N/A 
20 20.9 N/A 1.1 N/A 4.5 N/A 
*AQ-312 was only tested at concentration of 1 μM due to the insufficient amount. 
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3.2.4. Recovery from plasma 
The recovery of AQ compounds from plasma extraction was determined as R, and R = 
drug extracted from plasma/drug in mobile phase × 100%. Table 3-3 shows the results of 
recovery after extraction process. The recovery of AQ-290 was no less than 65% and that of AQ-
284 was no less than 50%, which are acceptable for performing PK study. The recoveries of AQ-
313 and AQ-312 were around 100%, which was desirable for the following PK study. In each 
case, the extraction of α-NF was above 85%. 
Table 3-3 Recovery from plasma (n = 3) 
Concentration 
(μM) 
Recovery (%)*   
AQ-284 AQ-290 AQ-313 AQ-312** 
α-NF 
(Waters) 
α-NF 
(Agilent) 
1 N/A N/A 105.7±1.2 99.5±1.1 N/A N/A 
2 55.8±3.5 69.2±1.1 N/A N/A 89.2±3.8 91.4±2.5 
10 58.3±2.3 76.3±3.1 107.6±1.9 N/A N/A N/A 
20 53.2±2.6 86.7±4.3 94.9±1.9 N/A N/A N/A 
          * Mean ± RSD;  
          **AQ-312 was only tested at concentration of 1 μM due to the insufficient amount. 
3.3.  Pharmacokinetic Study 
The plasma was collected at 3 min, 15 min and 30 min following IV injection of AQ-284 
in mice. The chromatograms of in-vivo analysis have been shown as Figure 3-7(b). The AQ-284 
peak with a barely detective area was observed at 3 min following IV injection, indicating 
negligible amount of AQ-284 in murine plasma. A possible metabolite peak was observed in the 
in-vivo chromatograms with a retention time of 9 min as shown in Figure 3-7(c). In comparison, 
Figure 3-7(a) was AQ-284 spiked in plasma sample in vitro, which clarified the unknown peak 
was not any endogenous constituent. For AQ-290, the plasma was collected at 2 min and 15 min 
following IV injection. However, no AQ-290 peak was observed.  
The PK profile of AQ-312 is shown in Figure 3-5. The plasma was collected at 2 min 
and 8 min from mice following IV injection. The elimination half-life (t1/2) of AQ-312 was 
approximately 2 min from the PK profile. A new peak matching with the maximum absorbance 
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wavelength of AQ-312 (258 nm) was observed at 8 min. The chromatograms of AQ-312 are 
shown in Figure 3-8. 
 
Figure 3-5 PK profile for AQ-312: IV injection. 
 
For AQ-313, the plasma samples were collected at 2 min, 30 min, 60 min and 120 min, 
respectively after IV injection in mice. The concentration of AQ-313 in systemic circulation of 
mice was around 30 μM 2 min after IV administration. However, no AQ-313 peak was observed 
after 30 min, indicating AQ-313 were eliminated from mice circulation within 30 min.  
3.4.  Stability Study  
The stabilities of AQ compounds were evaluated in plasma as well as in sodium 
phosphate buffer (pH = 7.4) using degradation half-life (t1/2) as a parameter. The results are 
demonstrated in Figure 3-6 and Table 3-4. The t1/2s of AQ-284, AQ-290 and AQ-312 were no 
more than 15 min in plasma. The three AQ compounds degraded rapidly in buffer as well, but 
with greater t1/2s than in plasma. In comparison, AQ-313 was more stable in plasma or in buffer. 
Approximate no more than 20% of AQ-313 have been degraded after incubation at 37 ℃ for 30 
min in plasma or 24 h in buffer.  
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Figure 3-6 Stability of AQ compounds after incubation at 37 ℃: (a) in plasma in vitro; (b) in 
phosphate buffer (pH 7.4). 
Table 3-4 Degradation half-life (t1/2) at 37 ℃ 
Compound 
Code 
t1/2 
            In plasma (min) In phosphate buffer (pH 7.4) (h) 
AQ-284 3.9 6.0 
AQ-290 5.0 1.3 
AQ-312 11.7 4.5 
AQ-313              > 30              > 24 
 
 
3.5.  Influence of Hemolysis  
The in-vivo chromatograms of AQ-284 and AQ-312 had shown the peak of metabolites. 
Since DMSO would cause hemolysis in vivo, which might impair the integrity of the compounds, 
the influence of hemolysis was incorporated into consideration. The results have been shown in 
Figure 3-7 and Figure 3-8 for AQ-284 and AQ-312, respectively. 
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(a) 
(b) 
(c) 
Figure 3-7 Chromatogram of AQ-284 at 258 nm: (a) normal plasma in vitro; (b) in vivo 
following IV injection; (c) hemolyzed plasma in vitro. 
 
 No AQ-284 peak was found with a retention time of 13 min. However, the possible 
metabolite was observed with the retention time of 9.5 min and also had the same maximum 
absorbance wavelength with AQ-284. This indicated the metabolite was caused by hemolysis. 
AQ-284 peak at 13.1 min 
α-NF at 22.9 min 
Metabolite at 9.5 min 
α-NF at 22.9 min 
Metabolite at 9.5 min 
α-NF at 22.9 min 
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(a) 
 
(b) 
 
(c)   
 
Figure 3-8 Chromatogram of AQ-312 at 258 nm: (a) normal plasma in vitro; (b) in vivo 
following IV injection; (c) hemolyzed plasma in vitro. 
 
 
The influence of hemolysis was tested for AQ-312 as well. According to the results, 
hemolysis has no influence on the integrity of AQ-312, and the metabolite detected from 
chromatograms following IV injection might be caused by hepatic metabolism. 
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α-NF  
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CHAPTER 4 DISCUSSIONS 
Detective and quantitative methods using HPLC were established for AQ-284 and AQ-
290 (Waters HPLC system) as well as AQ-312 and AQ-313 (Agilent HPLC system). The HPLC 
methodology had high selectivity and specificity for each compound because of the complete 
resolution without interference. RE and RSD obtained from accuracy and precision assay were 
below 15%, demonstrating that the assay for each compound was precise, accurate and 
consistent at daily laboratory conditions, and the errors from manually operation were 
neglectable.  
Although AQ compounds share a similar anthraquinone scaffold, they possess variable 
physicochemical properties because of the diverse modifications on the rhein scaffold. AQ-313 
was extracted from plasma using acetonitrile with the recovery close to 100%. However, 
extraction using acetonitrile for AQ-284, AQ-290 and AQ-312 was less favored than using ethyl 
acetate, indicating that AQ-313 was less lipophilic than the others.  
According to the stability studies at 37 ℃, AQ-284 and AQ-290 were highly unstable in 
plasma, which accounts for the significance of low-temperature (4 ℃) extraction to obtain high 
recoveries of those two compounds. However, extraction at 4 ℃ would slowdown but never 
cease the degradation of AQ-284 and AQ-290. Therefore, the optimal vortex-mixing time was 
necessary to be determined, at which the degradation of compounds had minimal compromise on 
solvent-solvent extraction. The narrow standard deviations (RSD) of repetitive recovery tests 
implied that the extraction methods for all AQ compounds were reproducible. However,
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considering the relatively high LLoQ (2 μM) and low recoveries of AQ-284 and AQ290 (no 
more than 80%), more volume of mice blood have been drawn to enhance the chance of drug 
quantification in plasma. The recoveries of AQ-312 and AQ-313 exceeded 100%, which was 
possibly due to the matrix effect of plasma extracts or errors from manually aliquoting. In sum, 
the established methodologies were reliable and desirable for PK studies. 
Results from PK studies showed all AQ compounds were rapidly eliminated from mice 
circulation. Little AQ-284 and AQ-290 were detected in plasma following IV injection. Since the 
drug would be delivered to organs as rapidly as the rate of injection, metabolism in vivo, 
especially the hepatic metabolism, would inactivate AQ-284 and AQ-290 very fast. A peak of 
metabolite from AQ-284 was observed with a retention time of 6.5 min (retention time of AQ-
284 was 13 min). The peak of metabolite had the same UV absorbance chromatogram with AQ-
284. Since thiol group is one of the most abundant and active functional groups of proteins, the 
chloride group of AQ-284 was likely substituted by thiol group of certain proteins. However, no 
further study was performed to identify the structure of this metabolite. The structures of AQ-
312 and AQ-313 were slightly different compared to AQ-284 and AQ-290, which have induced 
azide functional group. However, the AQ-312 and AQ-313 had very short t1/2s as well. A 
metabolite from AQ-312 was found during PK study, which was likely caused by hepatic 
metabolism. 
According to the results from stability studies, AQ-284, AQ-290 and AQ-312 were found 
susceptible to hydrolysis with t1/2s shorter than 6 h in sodium phosphate buffer. In plasma, their 
degradations were significantly accelerated with the t1/2s no more than 15 min. The majority of 
enzymes in plasma exert and facilitate functions of hydrolysis, which could account for the faster 
degradations in plasma than in buffer. The chemical instability in solution was one possible 
reason to explain why the three compounds all had very short t1/2s in vivo.  Although AQ-313 
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have showed higher stability than the other three compounds, it was eliminated from mice 
circulation very quickly as well. Therefore, even bearing a stronger chemical stability, AQ-313 
also was inactivated by in-vivo metabolism rapidly.  
All AQ compounds were chemically different, yet no solid evidence to give clear 
correlation of their in-vitro stability and in-vivo t1/2. For compounds that are very unstable in 
vitro, they would very likely be inactivated by metabolism in vivo rapidly. However, for 
compounds with higher chemical stability, they could also be inactivated by metabolism quickly. 
Therefore, the stability in liver homogenate may give some indications for their PK properties. 
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CHAPTER 5 CONCLUSIONS 
AQ compounds were promising anticancer drugs which exert the anti-cancer activities by 
blocking the interaction between MDM2 and p53. The HPLC assay methodologies and plasma 
extraction methods described above were specific, accurate and reproducible for the 
determination of AQ compounds in murine plasma for pharmacokinetic study. All AQ 
compounds were found rapidly eliminated from the murine systemic circulation likely due to 
rapid metabolism in vivo, which caused by their chemical instabilities or rapid hepatic 
inactivation. More cases and studies are needed to draw a predictable correlation between in-
vitro stability and PK properties. 
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